Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/20/2024 | $48.00 → $2.00 | Outperform → Sector Perform | RBC Capital Mkts |
| 11/15/2024 | $50.00 → $48.00 | Outperform | RBC Capital Mkts |
| 12/2/2022 | Neutral → Underperform | BofA Securities | |
| 2/17/2022 | $15.00 → $8.00 | Buy | HC Wainwright & Co. |
| 2/16/2022 | $3.00 → $4.00 | Outperform | SVB Leerink |
| 11/12/2021 | $6.00 | Overweight → Equal-Weight | Morgan Stanley |
| 11/11/2021 | $21.00 → $15.00 | Buy | HC Wainwright & Co. |
| 11/10/2021 | $28.00 → $10.00 | Outperform | SVB Leerink |
DEFA14A - HOOKIPA Pharma Inc. (0001760542) (Filer)
8-K - HOOKIPA Pharma Inc. (0001760542) (Filer)
DEFA14A - HOOKIPA Pharma Inc. (0001760542) (Filer)
Encouraging clinical activity with observed deepening of responses in 35 evaluable first line head and neck patients treated with HB-200 plus pembrolizumabIn a subset of 17 evaluable patients with PD-L1 combined positive score (CPS) of 20 or higher, the Company's selected registrational pivotal trial population, data showed confirmed ORR of 53%, CR rate of 18%, and DCR of 82%Preliminary progression-free survival (PFS) was 16.3 months and preliminary overall survival (OS) rate was 88% at 9 months for the CPS 20 or higher subgroup, comparing favorably to current standard of careCompany will host a conference call at 4:15 p.m. ET today NEW YORK and VIENNA, June 04, 2024 (GLOBE NEWSWIRE) -- H
Phase 2/3 pivotal trial design and protocol for HB-200 in combination with pembrolizumab for the first-line treatment of patients with HPV16+ recurrent or metastatic OPSCC aligned with FDA feedback HB-200 accepted for oral abstract presentation at ASCO 2024 Annual Meeting with data from approximately 40 patients treated with HB-200 in combination with pembrolizumab Two additional abstracts for HB-200 and HB-700 accepted for the ASCO 2024 Annual Meeting Company to host investor call at 8:00 a.m. ET on Thursday, April 25, 2024, to highlight path to potential registration; participant details below NEW YORK and VIENNA, Austria, April 25, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDA
NEW YORK and VIENNA, Austria, Nov. 02, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, ‘HOOKIPA'))), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that it will release its third quarter 2023 financial results and business highlights on November 9, 2023. The company will not be conducting a conference call in conjunction with this financial release. About HOOKIPAHOOKIPA Pharma Inc. (NASDAQ:HOOK) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies, based on its proprietary arenavirus platform, which are designed to mobilize and amplify targeted T cells and thereby fight o
NEW YORK and VIENNA, Austria, Jan. 07, 2025 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, "HOOKIPA", the "Company")), a clinical-stage biopharmaceutical company developing next generation immunotherapeutics for the treatment of cancer and serious infectious disease, today announced a notice to shareholders regarding U.K. disclosure requirements. HOOKIPA directs the attention of its shareholders to certain disclosure requirements applicable to the potential all-share acquisition by HOOKIPA of Poolbeg Pharma plc, which was announced on January 2, 2025. HOOKIPA's shares are admitted to trading on the NASDAQ Capital Market exchange. The relevant disclosure requirements are set out in
Enrollment of 68 patients completed Phase 2 study for eseba-vec + pembrolizumab in HPV+ HNSCC four months ahead of schedule SITC 2024 late-breaking poster highlights Phase 2 eseba-vec data updates for increased number of patients reflecting ORR and durability in line with prior data First patients dosed in Phase 2 investigator led study with MSKCC in new clinical setting as adjuvant therapy for head and neck cancer Strength of HB-700 KRAS-inhibitor program highlighted by preclinical dataset presented at recent RAS Targeted Drug Development Summit NEW YORK and VIENNA, Austria, Nov. 14, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, "HOOKIPA", the "Company")
NEW YORK and VIENNA, Nov. 11, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, "HOOKIPA", the "Company")), a clinical-stage biopharmaceutical company developing next generation immunotherapeutics for the treatment of cancer and serious infectious disease, today announced that clinical collaborator Alan Ho, MD, PhD, Chief of the Head and Neck Oncology Service at Memorial Sloan Kettering Cancer Center, presented updated Phase 2 data from a study evaluating eseba-vec in combination with pembrolizumab as front line (1L) therapy in the setting of human papillomavirus type 16 positive (HPV16+) relapsed or metastatic head and neck squamous cell carcinoma (R/M HNSCC) at the 39th Annual M
4 - HOOKIPA Pharma Inc. (0001760542) (Issuer)
4 - HOOKIPA Pharma Inc. (0001760542) (Issuer)
4 - HOOKIPA Pharma Inc. (0001760542) (Issuer)
RBC Capital Mkts downgraded HOOKIPA Pharma from Outperform to Sector Perform and set a new price target of $2.00 from $48.00 previously
RBC Capital Mkts reiterated coverage of HOOKIPA Pharma with a rating of Outperform and set a new price target of $48.00 from $50.00 previously
BofA Securities downgraded HOOKIPA Pharma from Neutral to Underperform
SC 13G/A - HOOKIPA Pharma Inc. (0001760542) (Subject)
SC 13G/A - HOOKIPA Pharma Inc. (0001760542) (Subject)
SC 13G - HOOKIPA Pharma Inc. (0001760542) (Subject)
Enrollment of 68 patients completed Phase 2 study for eseba-vec + pembrolizumab in HPV+ HNSCC four months ahead of schedule SITC 2024 late-breaking poster highlights Phase 2 eseba-vec data updates for increased number of patients reflecting ORR and durability in line with prior data First patients dosed in Phase 2 investigator led study with MSKCC in new clinical setting as adjuvant therapy for head and neck cancer Strength of HB-700 KRAS-inhibitor program highlighted by preclinical dataset presented at recent RAS Targeted Drug Development Summit NEW YORK and VIENNA, Austria, Nov. 14, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, "HOOKIPA", the "Company")
NEW YORK and VIENNA, Aug. 30, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK) ("HOOKIPA" or the "Company"), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced the appointment of Director Julie O'Neill as Non-Executive Chair of the Company's Board of Directors. She succeeds Jan van de Winkel, who has decided to step down from the Board effective August 30, 2024, due to increasing time commitments from his executive position as Chief Executive Officer of Genmab A/S. The Company also announced that Tim Reilly has chosen to step down from the Board, also effective August 30th, to be able to dedicate more time to his o
New Leadership Appointments; Positive Clinical and Regulatory Reports for the Lead Product Candidate, HB-200 (eseba-vec); On track to initiate the Phase 2/3 "AVALON-1" study with eseba-vec in Q4 2024 ASCO 2024 Presentation: Reported best-in-class Phase 2 data for first-line HPV16+ head and neck cancer patients treated with eseba-vec (formerly HB-200) in combination with pembrolizumab during oral presentation at the American Society of Clinical Oncology (ASCO) 2024 Annual MeetingRegulatory Progress: Announced alignment with U.S. Food and Drug Administration (FDA) for the AVALON-1 Phase 2/3 pivotal trial design and protocol for eseba-vec, in combination with pembrolizumab for the first-li